RecurX Bio, Inc

Recur X Bio - Summary RecurX Bio's phenotypic microfluidic assay captures the deadly cell sub population responsible for cancer metastasis and rapid spread. Our test is used to Determine how serious is the patient's disease, Reveal how well the Standard of Care treatment will work Uncover better existing drugs Discover new cancer drugs Prevent unnecessary side effects from drugs that do not work We are planning to go to market with tests for Glioblastoma first followed likely by metastatic brain cancer and breast cancer We are seeking to collaborate with pharmaceutical companies to provide more effective drug development. Approximately 97%+ of cancer drugs fail in development and clinical trials, in part because laboratory models do not accurately represent what happens in the body during metastasis. Better technology is necessary to bring much needed drugs to market. New drug discovery can potentially occur faster, less expensively and with greater success using RecurX Bio's technology. Our technology is designed to screen and select drug candidates for preclinical and clinical testing and to identify unique drugable targets in the most deadly cells captured by our technology. Discovery, translation and clinical research in breast cancer and glioblastoma is being carried ourt in the labs of Prof Kostas Konstantopoulos and Dr Alfredo Quinones - Hinojosa at Johns Hopkins and Mayo Clinic respectively with $9m in NIH funding to date and more to come. Two Nature Biotechnology publications have resulted and 3 patents.

• Employees 1
• Founded 2020